000028 国药一致
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入56,466,354-0.21%75,477,48573,443,13768,357,81059,649,455
减:营业总成本55,384,5960.73%73,277,09771,309,68866,519,74757,817,567
    其中:营业成本50,326,3260.56%66,425,42664,516,92660,339,29852,591,767
               财务费用183,05847.51%204,535189,514212,483119,855
               资产减值损失(10,762)24.43%(17,577)(71,588)(242,905)(5,179)
公允价值变动收益3,149-81.93%(15,161)28,871----
投资收益254,93112.27%237,029139,131292,381283,952
    其中:对联营企业和合营企业的投资收益310,43533.55%315,446298,527333,397354,346
营业利润1,344,445-26.25%2,467,4252,306,0691,952,4112,163,841
利润总额1,356,463-25.49%2,473,2272,311,0701,974,8532,157,236
减:所得税费用260,794-29.56%514,739539,332447,211435,940
净利润1,095,669-24.45%1,958,4871,771,7381,527,6421,721,296
减:非控股权益30,127-88.44%359,231285,030191,214319,404
股东净利润1,065,542-10.43%1,599,2561,486,7081,336,4281,401,893

市场价值指针
每股收益 (元) *1.910-10.75%2.8702.6703.1203.270
每股派息 (元) *----0.6800.8000.6000.800
每股净资产 (元) *32.5246.65%31.29037.66634.86132.580
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容